.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,333,263

« Back to Dashboard

Details for Patent: 9,333,263

Title:Device for transdermal administration of drugs including acrylic based polymers
Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Inventor(s): Kanios; David (Palmetto Bay, FL)
Assignee: NOVEN PHARMACEUTICALS, INC. (Miami, FL)
Filing Date:May 15, 2015
Application Number:14/713,252
Claims:1. A method of making a transdermal drug delivery system comprising, forming a carrier composition comprising a blend of (a) a polymer composition comprising at least one acrylic-based polymer polymerized from monomers that consist of (i) soft acrylic monomers selected from the group consisting of 2-ethyl hexyl acrylate, isobutyl acrylate, ethyl acrylate, butyl acrylate, dodecyl methacrylate, 2-ethylhexyl methacrylate, 2-ethoxyethyl acrylate, isopropyl acrylate, and 2-methoxyethyl acrylate, in an amount of 20% by weight of the acrylic-based polymer; and (ii) hard acrylic monomers selected from the group consisting of methacrylate, N-butyl acrylate, acrylic acid, butyl methacrylate, ethyl methacrylate, methyl methacrylate, hexyl methacrylate, and methyl acrylate, in an amount of 80% by weight of the acrylic-based polymer; and (b) a drug in an amount of from 0.1% to 50% by weight of the carrier composition, wherein all acrylic-based polymers present in said polymer composition of the transdermal drug delivery system are polymerized from monomers that consist of monomers selected from the group consisting of said soft and hard acrylic monomers (i) and (ii).

2. The method according to claim 1, wherein the drug is methylphenidate.

3. The method according to claim 1, wherein the drug is amphetamine.

4. The method according to claim 1, wherein the drug is present in said transdermal drug delivery system from about 1% to about 10% by weight.

5. The method according to claim 1, wherein the soft acrylic monomer comprises 2-ethyl hexyl acrylate.

6. The method according to claim 1, wherein the hard acrylic monomer comprises methacrylate.

7. The method according to claim 1, wherein the acrylic-based polymer is present in an amount of from 2 to 95% by weight of the carrier composition, based on the dry weight of the carrier composition.

8. The method according to claim 1, further comprising applying the polymer composition on a release liner.

9. The method according to claim 8, further comprising applying a backing layer to the polymer composition applied on a release liner.

10. The method according to claim 1, further comprising applying the polymer composition on a backing layer.

11. The method according to claim 10, further comprising applying a release liner to the polymer composition applied on a backing layer.

12. A method of making a transdermal drug delivery system comprising, forming a carrier composition comprising a blend of: (a) a polymer composition of at least one acrylic-based polymer which acrylic-based polymer is polymerized with monomers that include: (i) a soft acrylic monomer having a glass transition temperature (T.sub.g) from about -70 C to about -10 C in an amount of from about 20 to about 70% by weight of the acrylic-based polymer; and (ii) a hard acrylic monomer having a glass transition temperature (T.sub.g) from about -5 C to about 120 C in an amount of from about 30 to about 80% by weight of the acrylic-based polymer, wherein said acrylic based polymers are not polymerized with methacrylic acid monomers; and (b) a drug in an amount of from 0.1% to 50% by weight of the carrier composition.

13. The method according to claim 12, wherein the drug is methylphenidate.

14. The method according to claim 12, wherein the drug is amphetamine.

15. The method according to claim 12, wherein the drug is present in said transdermal drug delivery system from about 1% to about 10% by weight.

16. The method according to claim 12, wherein the soft acrylic monomer is selected from the group consisting of 2-ethyl hexyl acrylate, isobutyl acrylate, ethyl acrylate, butyl acrylate, dodecyl methacrylate, 2-ethylhexyl methacrylate, 2-ethoxyethyl acrylate, isopropyl acrylate, and 2-methoxyethyl acrylate.

17. The method according to claim 12, wherein the soft acrylic monomer comprises 2-ethyl hexyl acrylate.

18. The method according to claim 12, wherein the hard acrylic monomer is selected from the group consisting of methacrylate, N-butyl acrylate, acrylic acid, butyl methacrylate, ethyl methacrylate, methyl methacrylate, hexyl methacrylate, and methyl acrylate.

19. The method according to claim 12, wherein the hard acrylic monomer comprises methacrylate.

20. The method according to claim 12, further comprising applying the polymer composition on a release liner.

21. The method according to claim 20, further comprising applying a backing layer to the polymer composition applied on a release liner.

22. The method according to claim 12, further comprising applying the polymer composition on a backing layer.

23. The method according to claim 22, further comprising applying a release liner to the polymer composition applied on a backing layer.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc